eliquis apixaban logo eliquis apixaban logo eliquis apixaban logo

This information is intended for healthcare professionals based in the UK.

If you are not a healthcare professional in the UK, please click here.

For Prescribing and Adverse Event reporting information, click here.

desk-img mob-img

Eliquis (apixaban) range of indications

ELIQUIS – an oral, direct factor Xa inhibitor – is indicated for:

  • Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥II)1
  • Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults1
  • Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery1

Learn about ELIQUIS for your patients with NVAF

Learn about ELIQUIS for your patients with
DVT / PE

Choose ELIQUIS for your patients with NVAF or DVT / PE

See ELIQUIS SmPC for full prescribing information

Diagnosemethoden

ELIQUIS is available for your patients with
DVT / PE1


ELIQUIS (apixaban) SmPC

Please click here to access the ELIQUIS SmPC.

ELIQUIS (apixaban) Patient Information Leaflet

Please click here to access the ELIQUIS Patient Information Leaflet.

DVT = Deep Vein Thrombosis   
NVAF = Non-Valvular Atrial Fibrillation   
NYHA = New York Heart Association   
PE = Pulmonary Embolism   
TIA = Transient Ischaemic Attack   
VTE = Venous Thromboembolic Events

Reference

  1. ELIQUIS® (apixaban) Summary of Product Characteristics.